HEALTH STATE VALUES IN ALZHEIMER'S DISEASE - BASELINE RESULTS FROM A LARGE PROSPECTIVE OBSERVATIONAL STUDY IN THREE EUROPEAN COUNTRIES (GERAS)

被引：0

作者：

Reed, C. ^{[1
]}

Argimon, J. ^{[2
]}

Belger, M. A. ^{[1
]}

Bruno, G. ^{[3
]}

Dodel, R. ^{[4
]}

Happich, M. ^{[5
]}

Haro, J. M. ^{[6
]}

Jones, R. W. ^{[7
]}

Vellas, B. ^{[8
]}

Wimo, A. ^{[9
]}

机构：

[1] Eli Lilly & Co, Windlesham, Surrey, England

[2] Serv Catala Salut, Barcelona, Spain

[3] Univ Rome, Rome, Italy

[4] Univ Marburg, Marburg, Hessen, Germany

[5] Eli Lilly & Co, Bad Homburg, Germany

[6] Univ Barcelona, Barcelona, Spain

[7] Royal United Hosp, Rice Ctr, Bath BA1 3NG, Avon, England

[8] Toulouse Univ Hosp, Toulouse, France

[9] Karolinska Inst, Stockholm, Sweden

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 07期

关键词：

D O I：

10.1016/j.jval.2012.08.1972

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A554 / A554

页数：1

共 50 条

[1] The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries - Study Design and Baseline Findings
Wimo, Anders
Reed, Catherine C.
Dodel, Richard
Belger, Mark
Jones, Roy W.
Happich, Michael
Argimon, Josep M.
Bruno, Giuseppe
Novick, Diego
Vellas, Bruno
Maria Haro, Josep
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2013, 36 (02) : 385 - 399
[2] HEALTH CARE RESOURCE USE AND COST IN ALZHEIMER'S DISEASE IN THREE EUROPEAN COUNTRIES - BASELINE FINDINGS OF THE GERAS STUDY
Reed, C.
Argimon, J.
Belger, M. A.
Bruno, G.
Dodel, R.
Happich, M.
Haro, J. M.
Jones, R. W.
Vellas, B.
Wimo, A.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A527 - A527
[3] Costs associated with Alzheimer's disease in Italy: baseline results from the GERAS II observational study
Bruti, G.
Bruno, G.
Mancini, M.
Reed, C.
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 : S61 - S62
[4] Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS)
Reed, C.
Lebrec, J.
Dell'agnello, G.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 249 - 249
[5] Determinants of societal costs in Alzheimer's disease: GERAS study baseline results
Dodel, Richard
Belger, Mark
Reed, Catherine
Wimo, Anders
Jones, Roy W.
Happich, Michael
Argimon, Josep M.
Bruno, Giuseppe
Vellas, Bruno
Maria Haro, Josep
[J]. ALZHEIMERS & DEMENTIA, 2015, 11 (08) : 933 - 945
[6] Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS; encore from 2016 EAN)
Ueda, K.
Reed, C.
Lebrec, J.
Dell'Agnello, G.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1026 - 1026
[7] COMPARING RESOURCE USE IN ALZHEIMER'S DISEASE ACROSS THREE EUROPEAN COUNTRIES-18-MONTH RESULTS OF THE GERAS STUDY
Belger, M.
Arigmon, J. M.
Dodel, R.
Haro, J. M.
Wimo, A.
Reed, C.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A759 - A760
[8] Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study
Nakanishi, Miharu
Igarashi, Ataru
Ueda, Kaname
Brnabic, Alan J. M.
Treuer, Tamas
Sato, Masayo
Kahle-Wrobleski, Kristin
Meguro, Kenichi
Yamada, Masahito
Mimura, Masaru
Arai, Heii
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (01) : 127 - 138
[9] Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study
Rapp, Thomas
Andrieu, Sandrine
Chartier, Florence
Deberdt, Walter
Reed, Catherine
Belger, Mark
Vellas, Bruno
[J]. VALUE IN HEALTH, 2018, 21 (03) : 295 - 303
[10] Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study
Olazaran, Javier
Aguera-Ortiz, Luis
Maria Argimon, Josep
Reed, Catherine
Ciudad, Antonio
Andrade, Paula
Dilla, Tatiana
[J]. INTERNATIONAL PSYCHOGERIATRICS, 2017, 29 (12) : 2081 - 2093

← 1 2 3 4 5 →